SpeedWeed

AUGUST 4, 2021

After watching my brother self-medicate for his chronic pain for decades, I didn’t understand how cannabis was important to him as a medicine. I always thought he used his chronic pain as an “excuse” to self-administer what I thought was a toxic drug. . in 2014, I watched my brother walk into a cannabis clinic.

Chronic Pain

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. Draft Law of Ukraine. ARV (revised). REFERENCE to the EU acquis. explanatory note. Comparative table.

Seed-To-Sale

Cannabis Law Report

DECEMBER 28, 2021

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. Virpax initially focused strictly on pain product candidates. Virpax anticipates enrollment of the first patient by early second quarter of 2022. to conduct this study in Canada.

Pharmaceutical

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. The studies are expected to begin in January of 2022.

Research and Development

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. Sinclair is expected to begin the preclinical animal studies at the beginning of 2022 as part of the enabling trials for an IND application with the FDA.

Pharmaceutical

The Cannigma

MAY 13, 2022

One of the most common uses of medical cannabis is to treat chronic pain. In fact, modern research on cannabis and pain dates back to before 1975. Over 10% of US adults have suffered from some degree of daily pain for at least three months, so the need for improved treatment is clear. How cannabis can help with pain.

Terpenes

The Cannigma

DECEMBER 12, 2022

Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.

History

Cannabis Law Report

MAY 14, 2022

13 May 2022. By 2022, it is now difficult to find a high street or retail centre between John o’ Groats and Land’s End without CBD products for sale. However, observational studies have their limitations, which is why most have recently welcomed with open arms the UK Health Research Authority approved trial, Canpain.

Access

The Cannigma

JANUARY 13, 2023

While migraines are a commonly reported condition by patients in cannabis studies, there is little clinical research on how cannabis can influence migraine pain. 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.

Terpenes

Cannabis Law Report

JANUARY 5, 2022

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. The patent will be issued on January 11, 2022. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical

Veriheal

NOVEMBER 7, 2024

Because the categorization of a controlled substance determines its availability and accessibility, the benefits of rescheduling are important to patients suffering from chronic pain, epilepsy, and other conditions. drug policy and public opinion regarding cannabis’ status as a medicine.

DEA